8-K: Assembly Biosciences Executes 1-for-12 Reverse Stock Split to Regain Nasdaq Compliance

Assembly Biosciences has completed a 1-for-12 reverse stock split of its common stock, effective February 9, 2024, to meet Nasdaq's minimum bid price requirement.

Summary

• Assembly Biosciences implemented a 1-for-12 reverse stock split of its common stock.
• The reverse stock split became effective on February 9, 2024.
• Trading on a split-adjusted basis began on February 12, 2024, under the same ticker symbol ASMB but with a new CUSIP number 045396207.
• The number of outstanding shares was reduced from approximately 65.8 million to approximately 5.5 million, subject to adjustments for fractional shares.
• The reverse stock split was approved by stockholders at a special meeting on January 31, 2024.
• The primary purpose of the reverse stock split is to regain compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a necessary but not inherently positive action (reverse stock split) to maintain Nasdaq listing. It does not indicate a positive or negative outlook for the company's future performance.

Positives

• The reverse stock split is a necessary step to maintain the company's listing on the Nasdaq Global Select Market.
• The company has taken action to address the minimum bid price requirement.
• The reverse stock split will not alter any stockholder's percentage interest in the company's equity, except for fractional shares.

Negatives

• The reverse stock split was necessary due to the company's share price falling below Nasdaq's minimum bid price requirement.
• The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.

Risks

• The company's ability to maintain compliance with Nasdaq listing requirements is not guaranteed.
• The reverse stock split may not be sufficient to improve the company's long-term financial health.
• The company's future success depends on the development and commercialization of its antiviral therapeutics.

Future Outlook

The company expects its common stock to continue trading on the Nasdaq Global Select Market under the same symbol (ASMB) on a split-adjusted basis. The company's future success depends on its ability to develop and commercialize its antiviral therapeutics and maintain compliance with Nasdaq listing requirements.

Management Comments

• The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Global Select Market.

Industry Context

Reverse stock splits are a common action for companies facing delisting from major exchanges due to low share prices. This action is not unique to Assembly Biosciences and is often a measure to regain compliance and maintain access to capital markets.

Comparison to Industry Standards

• Many biotechnology companies with struggling share prices have implemented reverse stock splits to maintain their Nasdaq listing.
• For example, companies like Cassava Sciences and Ocugen have also recently undergone reverse stock splits to meet minimum bid price requirements.
• The 1-for-12 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.
• The success of a reverse stock split in improving a company's long-term prospects depends on the underlying business fundamentals and the company's ability to execute its strategy.

Corporate Governance

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares.
• The reverse stock split is intended to maintain the company's listing on the Nasdaq, which is important for investor confidence.
• The company's employees may be affected by the company's overall financial health and stock performance.

Next Steps

• The company will continue to trade on the Nasdaq Global Select Market under the same symbol (ASMB) on a split-adjusted basis.
• Registered stockholders holding pre-split shares are not required to take any action to receive post-split shares.
• Stockholders holding shares in certificate form will receive a transmittal letter from Equiniti with instructions.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stockholders, common stock, ASMB, Assembly Biosciences, share price